A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007116/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy and safety of two different dosing
regimens of brigatinib (AP26113) in participants with ALK-positive locally advanced or
metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with
crizotinib.
提供机构：
Vivli
创建时间：
2021-05-06
